15 results about "Insulin signalling" patented technology

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.

The invention relates to the technical field of biomedicine, and discloses an application of miR-3963 for improving insulin resistance in preparation of drugs. The invention provides application of an active component in preparation of a medicine for preventing and / or treating insulin resistance or insulin resistance related diseases. The active component comprises miR-3963 or other substances (such as miR-3963 agonists, mimics and the like) capable of increasing the content of miR-3963 in a body. Research finds that miR-3963 can respond to insulin stimulation increase, and the activity of an insulin signal channel is enhanced by targeted inhibition of expression of an SMPD1 gene, so that insulin resistance is effectively improved. According to the invention, a novel target with great potential is provided for developing a new generation of targeted drugs aiming at the root of diabetes, and a key clue is provided for the miRNA participating in the blood glucose homeostasis regulation and the generation mechanism of insulin resistance.

The invention discloses application of oxidized berberine and berberrubine in treatment of diabetic osteoporosis, and belongs to the technical field of biological medicine. Researches find that both oxidized berberine and berberrubine have the effect of treating diabetic osteoporosis, and can significantly improve the femur microstructure of a diabetic osteoporosis model animal, so that the femur microstructure recovers to a normal level; the blood glucose clearing capacity can be improved, the insulin resistance index is reduced, and the insulin signal channel function is recovered; the oxidative stress state of diabetic osteoporosis model animals can be relieved, the proinflammatory factor level is reduced, and the anti-inflammatory and anti-oxidation effects are achieved. The invention provides a new scheme and data support for the treatment of diabetic osteoporosis, has better curative effect, safety and economy than the prior art, and has important clinical transformation value.

The invention discloses an FSTL1 overexpression adeno-associated virus and application thereof, and aims to efficiently deliver a mouse source FSTL1 gene into mouse muscle cells by virtue of a virus infection mechanism by utilizing the targeting property of AAV1 type to muscle tissues. FSTL1 is overexpressed in mouse muscle tissue, muscle insulin signal transduction and glucose metabolism processes are adjusted from multiple dimensions of insulin signal channel activation, glucose transporter regulation and control and the like, and therefore the insulin sensitivity and glucose metabolism conditions of muscles in an obese mouse model are improved.

The invention discloses a mulberry leaf fermentation composition helpful for reversing insulin resistance and a preparation method thereof, relates to the technical field of mulberry leaf fermentation treatment, and solves the problem that in the prior art, a technology for preparing auxiliary materials for assisting diabetes treatment from mulberry leaves and related products do not exist. The mulberry leaf fermentation composition is prepared from a mulberry leaf extract, a highland barley extract, a bitter gourd extract, hawthorn powder, yam flour, lemon powder, fructo-oligosaccharide, water-soluble dietary fibers, resistant dextrin and a fermentation microbial preparation, wherein the highland barley extract is prepared by mixing a highland barley flavone extract and a highland barley polysaccharide extract according to a mass ratio of (4-6): 1. Through multi-channel combination of'inhibiting sugar absorption, enhancing insulin signals, protecting islet cells and improving metabolism ', insulin signal channels can be effectively improved, inflammatory oxidative stress can be relieved, glucose and lipid metabolism disorder can be regulated, and insulin resistance can be reversed.

The present disclosure relates to compounds and uses thereof, for example for treating disease associated with impaired insulin signaling and / or a metabolic disorder and / or an insulin resistance disease.

The invention belongs to the technical field of biological medicines, and particularly relates to application of fenerenone in preparation of a medicine for treating polycystic ovarian syndrome. According to the invention, the fenerenone is used as a high-selectivity non-steroidal salt corticoid receptor antagonist to regulate and control local and systemic inflammatory response of ovary, oxidative stress state, insulin signal pathway and serum hormone level, so that the core pathological mechanism of polycystic ovarian syndrome is intervened.

The present disclosure pertains to compositions that are suitable for use in modulating cellular glucose uptake. The compositions may include one or more of the following compounds: (1) adenovirus-36 E4orfl protein, a nucleic acid encoding an adenovirus-36 E4orfl protein, or combinations thereof (compound 1); (2) DLG1, a nucleic acid encoding DLG1, or combinations thereof (compound 2); and / or (3) a DLG1 agonist, a nucleic acid encoding a DLG1 agonist, or combinations thereof (compound 3). The present disclosure also pertains to methods of treating or preventing a metabolic disorder in a subject by administering a composition of the present disclosure to the subject.

The invention discloses application of forsythin in preparation of a medicine for preventing or treating heart failure complicated by insulin resistance, and relates to the technical field of biomedicine. According to the invention, a model animal C57BL / 6J mouse is taken as a carrier, and the treatment effect of forsythin on heart failure complicated by insulin resistance is researched. The invention researches that forsythin has the effects of improving glucose intolerance and insulin resistance of a heart failure complicated insulin resistance model mouse and reducing the serum insulin level of the heart failure complicated insulin resistance model mouse; the sensitivity of muscle, adipose tissue, heart and liver insulin signal channels of a heart failure complicated insulin resistance model mouse is improved. It is proved that forsythin can effectively prevent and treat insulin resistance caused by heart failure, and a new selection thought is provided for prevention or treatment of insulin resistance complicated by heart failure at present.

The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and / or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.

The application discloses application of KIDINS220 in preparation of products for assisting in diagnosis of obesity or treatment of obesity, and belongs to the technical field of biological medicine. The application finds that hybrid mutation of KIDINS220 gene leads to reduction of protein expression of KIDINS220, and then reduces combination with AKT2, and causes reduction of phosphorylation level of AKT signal path; AKT2 is a core kinase of insulin signal in adipose tissue, and disorder of activation of AKT2 can cause reduction of glucose uptake, increase of lipid synthesis, and finally cause obesity. An agent for promoting interaction between KIDINS220 gene or protein and AKT2 and a polypeptide for specifically recognizing and combining KIDINS220 and AKT2 can be used for treatment of obesity. The treatment strategy has higher molecular specificity and safety, and is more suitable for large-scale application of overweight and mild to moderate obesity population.

The present application provides modified Chymotrypsin-like ELAstase 2A (CELA2A) proteins such as catalytically inactivate and protease resistant CELA2A proteins. Also provided herein are the uses of the CELA2A proteins for preserving pancreatic islet size, number as well as enhancing insulin secreting and insulin signaling and for the treatment of diabetes, pancreatitis and other related diseases.

The temperature monitoring system and method of the present application, the temperature monitoring system comprises a liquid accumulator, a push rod and a signal transmission module, the liquid accumulator is movably connected with a piston, wherein the piston is provided with a temperature sensor for detecting the temperature of insulin in the liquid accumulator; the push rod can push the piston to make the piston extrude the insulin in the liquid accumulator; the signal transmission module is installed on the piston and / or the push rod, and the signal transmission module can be signal connected with the temperature sensor under the driving of the piston and / or the push rod. The present application can realize the temperature detection of the insulin in the liquid accumulator, and then the insulin pump with the temperature monitoring system has the function of monitoring the temperature of the insulin when in use, so that whether the insulin in the insulin pump is inactivated due to the influence of temperature can be judged, and the patient can directly judge whether the insulin is effective; meanwhile, the temperature monitoring system has the effect of reducing power consumption when applied in the insulin pump.

The invention discloses a buckwheat and polygonatum sibiricum composition for improving type 2 diabetes and application of the buckwheat and polygonatum sibiricum composition in preparation of dairy products, and relates to the technical field of food, the composition comprises the following raw materials in parts by weight: 30-40 parts of buckwheat, 20-30 parts of polygonatum sibiricum, 15-25 parts of barley and 10-20 parts of wheat bran, and the dairy products are prepared by mixing a composition extracting solution and cow milk and then performing low-temperature fermentation. Bidirectional regulation of an intestinal flora-insulin signal channel is realized through compounding of the composition, and different from a single target effect in the prior art, different components in the composition respectively target the intestinal flora and an insulin-mTOR-autophagy signal channel; and the two components can promote each other (the intestinal flora metabolite SCFA can enhance the activity of an insulin signal channel) to form a two-way regulation closed loop, which is a core innovation point for realizing the comprehensive blood glucose reducing effect, and the ratio is an optimal scheme verified by early animal experiments, and the blood glucose reducing effect can be reduced when the ratio is deviated.

The invention provides a multi-dimensional evaluation method for insulin-resistant hepatocytes, which specifically comprises the following steps: performing phenotype screening on an insulin-resistant hepatocyte model, constructing a cell model and setting experimental groups; the influence on an insulin signal channel is verified through western blot; and finally performing comprehensive evaluation: when the phenotypic index is not matched with the mechanism index, further verifying the inspection range of time gradient, mitochondrial dynamics related protein or insulin signal pathway key protein so as to determine the subsequent research direction, and the method realizes in-situ correlation analysis of morphology, function and molecular pathways, is comprehensive in evaluation dimension, and is suitable for large-scale popularization and application. And in-depth research can be efficiently guided.